At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?
Answer from: Radiation Oncologist at Community Practice
At present, based on the randomised trial, it is approved for castrate resistant prostate cancer (can be chemo naive) with symptomatic bone only disease. In that situation, it improves all skeletal related events and survival and should be an indication to talk about this treatment. However, in prac...
Comments
Radiation Oncologist Thank you for your very helpful answer. Do you at...
Radiation Oncologist at Varian Medical Systems/Allegheny health network i feel response duration is lower becasue disease ...
Thank you for your very helpful answer. Do you at...
i feel response duration is lower becasue disease ...